Imagin Medical Inc. IMEXF Archives

MondayAug 30, 2021 2:29 pm

QualityStocksNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Closes on $3M Convertible Note Led by Rapha Capital

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures, has announced that Rapha Capital BioVentures Fund I, LP (“RCBVFI”) led and closed on a new convertible note offering totaling $3 million. The note, which was funded in three tranches, will support the clinical development of Imagin Medical’s flagship product: the i/Blue(TM) Imaging System. In addition, RCBVFI manager and leading urooncologist Dr. Kevin Slawin, MD, was appointed to Imagin’s board of directors, and Imagin also announced an updated website that features the company’s new logo and reflects the company’s…

FridayAug 27, 2021 10:23 am

QualityStocksNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Closes on $3M Convertible Note

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures, announced that it had secured a new convertible note totaling $3 million. Financing for the note, which was comprised of three tranches, was led by Rapha Capital BioVentures Fund I, LP (“RCBVFI”). The company anticipates using the funds to support the clinical development of its lead product, the i/Blue(TM) Imaging System. According to the company, the proprietary system is poised to increase patient access to this important technology. In addition to the funding, Imagin Medical also named Kevin…

TuesdayAug 17, 2021 12:20 pm

QualityStocksNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) to Demonstrate Advanced Capabilities of i/Blue Imaging System(TM) at AUA Annual Meeting

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced that the final design of its i/Blue Imaging System(TM) is on target to be demonstrated at the American Urology Association (“AUA”) Annual Meeting in September. In its 116th year, the AUA Annual Meeting is the largest gathering of urologists in the world, providing education and access to groundbreaking research, new guidelines and the latest advances in medicine for urologists and urologic health care professionals worldwide. Anticipating the ideal opportunity to address its target…

FridayAug 06, 2021 12:12 pm

QualityStocksNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Poised to Establish New Standard in Bladder Cancer Visualization

Imagin Medical (CSE: IME) (OTCQB: IMEXF) has developed the i/Blue Imaging System(TM), an innovative technology designed to significantly improve the way surgeons visualize cancerous cells for more accurate bladder resection. The patented technology, which has entered the manufacturing stage and is expected to be completed in 2022, allows for white and blue light images to be projected side-by-side simultaneously, enabling better surgical technique. It will also attach to most endoscopes currently on the market, protecting hospitals’ investment in instruments they already own and enabling their adoption of blue light cystoscopy at significant cost savings. A recent article reads, “With the…

ThursdayJul 29, 2021 9:30 am

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Proprietary Imaging System Set to Advance Bladder Cancer Visualization

Approximatively 75-85% of patients with confirmed cases of bladder cancer are diagnosed with non-muscle invasive (“NMIBC”) Imagin Medical’s innovative technology is targeting this type of bladder cancer and set to be completed in 2022 Blue light cystoscopy helps surgeons visualize the cancerous cells that are not detected by white light, enabling an improved resection Non-muscle-invasive bladder cancer (“NMIBC”) is a type of bladder cancer that has not infiltrated the other muscle tissues inside the bladder or spread to the lymph nodes. Approximately 75-85% of patients presenting with bladder cancer are diagnosed with NMIBC. The most common symptoms of NMIBC which…

ThursdayJul 01, 2021 2:47 pm

QualityStocksNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Finalizing Design of Innovative Cancer Visualization Technology

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is finalizing the design of its i/Blue Imaging System(TM), with manufacturing expected to be completed in 2022. The system is an innovative technology designed to significantly improve surgeons’ ability to visualize cancerous cells and enable more accurate bladder cancer resection. It solves challenges associated with using blue and white light cystoscopies, which require surgeons to switch back and forth between images and rely on memory to resect. “The company’s advanced technology will show both images simultaneously side-by-side on one screen, providing surgeons with better visualization to remove the cancer and making procedures more efficient,”…

WednesdayJun 23, 2021 2:14 pm

QualityStocksNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Setting Stage for Strengthened Demand for Blue Light Cystoscopy

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is working closely with manufacturing partner Lighthouse Imaging on its proprietary i/Blue Imaging System(TM) and is on target to conduct private demonstrations at the annual American Urology Association meeting set for early September. “The updated product design will incorporate changes intended to meet critical verification requirements established through benchmark testing of competitive systems and feedback from preliminary meetings with the FDA,” reads a recent article. “The additional testing and specification development focused on the contrast agent-induced fluorescence and the ability to replicate the clinical observations in bench-level settings. The sensitivity of the system can…

FridayJun 18, 2021 2:35 pm

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Making Advances in Bladder Cancer Treatment Through Proprietary Imaging Technology

Company’s i/Blue Imaging System(TM) is expected to be completed in 2022 The American Cancer Society estimates that 2021 will see 83,370 new cases of bladder cancer and approximately 17,200 deaths More than half of the patients who underwent a cystoscopy to remove non-muscle-invasive bladder cancer will experience recurrence The bladder cancer market was valued at $3.43 billion in 2020, and is anticipated to reach $4.71 billion by 2028 According to the American Cancer Society, new cases of bladder cancer in the United States are expected to reach 83,730 in 2021 and deaths are anticipated to reach 17,200 (https://ibn.fm/zNRWl). Approximately 50%…

ThursdayJun 17, 2021 2:43 pm

QualityStocksNewsBreaks – Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) Innovative System Expected to Lead to More Successful Surgical Outcomes

Imagin Medical (CSE: IME) (OTCQB: IMEXF) has developed and patented its i/Blue Imaging System(TM), which will directly address the problems associated with treating early stage bladder cancer using existing cystoscope technology. “Current technology shows only one image at a time, requiring the surgeon to constantly switch back and forth between the white and blue light images. The switching process makes orientation and navigation within the bladder a challenge for surgeons,” explains a recent article. Imagin’s system will display real-time white and blue light images simultaneously, side-by-side, removing the challenge of constantly switching and reorienting. In addition, unlike current BLC technology,…

FridayJun 11, 2021 9:00 am

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) on Course for Private Demonstrations of the i/Blue Imaging System(TM) at the American Urological Association Annual Conference in September

Further refinement of if the i/Blue Imaging System will incorporate changes intended to meet critical verification requirements established through benchmark testing of competitive systems as well as feedback from preliminary meetings with the FDA Bladder cancer is anticipated to cause over 1,000,000 physician consultations per year, resulting in $4 billion in total costs for bladder cancer treatment and management Imagin Medical plans to complete its proprietary i/Blue Imaging System in 2022 The National Cancer Institute (“NCI”) lists urinary bladder cancer as the sixth most prevalent form of cancer in the United States. In 2021, NCI estimates that the total number…

Site Search

Company Search

Tag: Imagin Medical Inc. IMEXF